Development of a Subcutaneous Fixed‐Dose Combination of Pertuzumab and Trastuzumab: Results From the Phase Ib Dose‐Finding Study

Adding pertuzumab to trastuzumab (both monoclonal antibodies targeting human epidermal growth factor receptor 2 [HER2]) has proven survival benefits when combined with chemotherapy for patients with HER2‐positive breast cancer. The combination of pertuzumab and trastuzumab together in 1 vial for sub...

Descripción completa

Detalles Bibliográficos
Autores principales: Kirschbrown, Whitney P., Wynne, Chris, Kågedal, Matts, Wada, Russ, Li, Hanbin, Wang, Bei, Nijem, Ihsan, Badovinac Crnjevic, Tanja, Gasser, Helena, Heeson, Sarah, Eng‐Wong, Jennifer, Garg, Amit
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
Pharmacokinetics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7027517/
https://www.ncbi.nlm.nih.gov/pubmed/30570763
http://dx.doi.org/10.1002/jcph.1362

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7027517/
https://www.ncbi.nlm.nih.gov/pubmed/30570763
http://dx.doi.org/10.1002/jcph.1362

Ejemplares similares